arrow
R

Robert A. Harrington

Weill Cornell Medicine
H指数:123
被引数:7.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)
2025-02-010
OAAI
Relationship of Oxidized Phospholipids and Lp(a) to Outcomes after Acute Coronary Syndrome: A Post Hoc Analysis of the ODYSSEY OUTCOMES Trial

氧化磷脂和Lp(a)与急性冠脉综合征后结局的关系:ODYSSEY OUTCOMES试验的事后分析

2024-11-120
PRE
Comparison of Lipoprotein(a) and Other Apo B Containing Lipoproteins as Predictors of Major Adverse Cardiovascular Events in ODYSSEY OUTCOMES

比较脂蛋白(a)与其他载脂蛋白B含量脂蛋白作为ODYSSEY OUTCOMES研究中主要不良心血管事件预测因子的研究

2024-11-120
PRE
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
2024-11-015
OAAI
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial

根据基线LDL-胆固醇水平输注载脂蛋白A-I和急性心肌梗死的心血管结局: AEGIS-II试验

2024-09-021
PRE
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients

阿司匹林用于男性和女性患者动脉粥样硬化性心血管疾病二级预防的剂量

2024-09-011
PRE
Contribution of Clinical Trial Event Data by Data Source A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial
2024-09-010
PRE
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

PCSK9抑制剂alirocumab的安全性: 来自47名296患者的见解-观察年

2024-04-206
OAAI
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES
2024-03-191
OA
Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial

慢性冠心病患者血运重建,治疗目标和结局的性别差异: 来自缺血试验的见解

2024-03-057
OAAI
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease

年龄和阿司匹林剂量在动脉粥样硬化性心血管疾病二级预防中的作用

2024-02-201
OAAI